The EVERY Company has secured $55 million in a Series D funding round. This funding will support the company’s expansion into the US market as it scales up its production of precision-fermented egg proteins. The round was led by McWin Capital Partners, with participation from a range of investors including Main Sequence, Bloom8, and Minerva Foods.
“EVERY is proving that biomanufacturing has the potential to transform the food industry”
EVERY’s fermentation-based technology has gained significant attention as an alternative to traditional egg proteins. Its offerings, such as OvoPro™ (a substitute for egg whites) and OvoBoost™ (a neutral protein for various food and beverage applications), are designed to replace conventional eggs in products across sectors such as baked goods, beverages, and protein supplements.
A stable solution for egg supply issues
Arturo Elizondo, CEO and Co-Founder of EVERY, stated, “This investment allows us to accelerate our mission of making egg protein more accessible, both in terms of availability and cost. We’re now positioned to scale up and reach consumers across the country, offering a stable and reliable source of protein that’s free from the risks associated with traditional egg farming.”
Walmart partnership for mass-market distribution
As part of its expansion strategy, EVERY is launching its proteins in Walmart stores across the United States starting this month. The rollout in the world’s largest retailer is a large step for the company, moving it from niche product offerings to mass-market availability. The funding from this round will help support the increased production capacity, particularly in the high-volume bakery sector, to meet this growing demand.
The growing interest in alternative proteins is largely driven by the increasing vulnerability of global food systems. Traditional egg production has faced challenges due to disease outbreaks, volatile feed prices, and environmental concerns.
EVERY’s approach, which decouples egg production from animal agriculture, provides a more stable and resilient solution. The company’s fermentation-based proteins are shelf-stable for up to 18 months, eliminating the need for refrigeration and making them easier to store and distribute compared to traditional liquid eggs.
The potential of EVERY’s tech
“EVERY’s technology has proven to be a game-changer. They’re not just conceptualizing new ideas—they are producing large quantities of egg protein at a commercial scale, providing food companies with a reliable solution to supply chain challenges,” noted Martin Davalos, Partner at McWin Capital Partners.
In addition to its commercial growth, EVERY’s product lineup continues to be well-received in both retail and foodservice channels. With a broad investor base that includes food giants like Grupo Bimbo and Grupo Nutresa, as well as high-profile backers like celebrity Anne Hathaway.
Phil Morle, Partner at Main Sequence, remarked, “EVERY is proving that biomanufacturing has the potential to transform the food industry. Their ability to deliver functional, scalable solutions to major food producers shows the strength of their platform.”
